Beta Bionics reported Q4 2025 sales growth, but analysts raised concerns about valuation and slower patient starts.

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited ...

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, ...

Investing.com - Beta Bionics, Inc. (NASDAQ:BBNX) is expected to deliver fourth-quarter 2025 revenue of "at least" $32.0 million, exceeding both Stifel’s estimate of $29.8 million and the Street’s ...

Investing.com - BofA Securities downgraded Beta Bionics, Inc. (NASDAQ:BBNX) from Buy to Neutral and lowered its price target to $28.00 from $33.00 on Friday. The stock is currently trading at $31.99, ...

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, ...

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring ...

On Monday, Stifel analysts began coverage of Beta Bionics, Inc. (NASDAQ:BBNX) shares with a Buy rating and a price target of ...

Beta Bionics (BBNX) reported preliminary, unaudited Q4 2025 net sales of at least $32M, compared to estimate of $28.9M, representing growth of at least 56% Y/Y. DME channel net sales are expected to ...

If your aggregate position is larger than Tier 1, your margin requirement will not be reduced by non-guaranteed stops. Please note: we have tried to ensure that the information here is as accurate as ...